Iradimed Co (IRMD) - Total Assets
Based on the latest financial reports, Iradimed Co (IRMD) holds total assets worth $114.39 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore IRMD debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Iradimed Co - Total Assets Trend (2012–2025)
This chart illustrates how Iradimed Co's total assets have evolved over time, based on quarterly financial data. See IRMD book value for net asset value and shareholders' equity analysis.
Iradimed Co - Asset Composition Analysis
Current Asset Composition (December 2025)
Iradimed Co's total assets of $114.39 Million consist of 74.7% current assets and 25.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.0% |
| Accounts Receivable | $13.67 Million | 12.6% |
| Inventory | $11.62 Million | 10.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.38 Million | 3.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Iradimed Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Iradimed Co.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Iradimed Co's current assets represent 74.7% of total assets in 2025, a decrease from 90.0% in 2012.
- Cash Position: Cash and equivalents constituted 47.0% of total assets in 2025, up from 30.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 4.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 12.6% of total assets.
Iradimed Co Competitors by Total Assets
Key competitors of Iradimed Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
Iradimed Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.13 | 8.87 | 10.90 |
| Quick Ratio | 6.15 | 7.62 | 10.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $74.30 Million | $66.66 Million | $62.34 Million |
Iradimed Co - Advanced Valuation Insights
This section examines the relationship between Iradimed Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.13 |
| Latest Market Cap to Assets Ratio | 10.68 |
| Asset Growth Rate (YoY) | 10.6% |
| Total Assets | $108.78 Million |
| Market Capitalization | $1.16 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Iradimed Co's assets at a significant premium (10.68x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Iradimed Co's assets grew by 10.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Iradimed Co (2012–2025)
The table below shows the annual total assets of Iradimed Co from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $108.78 Million | +10.63% |
| 2024-12-31 | $98.33 Million | +6.69% |
| 2023-12-31 | $92.16 Million | +7.77% |
| 2022-12-31 | $85.51 Million | +3.18% |
| 2021-12-31 | $82.88 Million | +16.62% |
| 2020-12-31 | $71.07 Million | +6.50% |
| 2019-12-31 | $66.73 Million | +37.75% |
| 2018-12-31 | $48.44 Million | +24.17% |
| 2017-12-31 | $39.01 Million | +4.89% |
| 2016-12-31 | $37.19 Million | +5.53% |
| 2015-12-31 | $35.24 Million | +51.20% |
| 2014-12-31 | $23.31 Million | +233.62% |
| 2013-12-31 | $6.99 Million | +25.79% |
| 2012-12-31 | $5.55 Million | -- |
About Iradimed Co
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs moni… Read more